When is radiopharmaceutical therapy most appropriately initiated in men with mCRPC?

A newly published paper by a team of Italian researchers has added a wrinkle to the critical questions about the most effective current and future forms of sequential therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Full data report from the ALSYMPCA trial of radium-223 presented

According to a company media release, the full results of the ALSYMPCA  trial were presented Saturday at the European Multidisciplinary Cancer Congress (EMCC). This is the trial of the injectable radioactive agent radium-223 chloride (Alpharadin®) in men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,157 other followers